CTOs on the Move

Rgenta Therapeutics

www.rgentatx.com

 
Rgenta Therapeutics is developing a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Our proprietary platform mines the massive genomics data to identify targetable RNA processing events and design small-molecule glues to modulate the interactions among the spliceosome, regulatory proteins, and RNAs
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Rgenta Therapeutics raised $20M on 04/02/2020
Rgenta Therapeutics raised $18M on 05/25/2021

Similar Companies

AOBiome

AOBiome LLC is developing first-in-class topical biologics for the treatment of inflammatory skin conditions. We have developed extensive scientific and manufacturing expertise on the use of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring bacteria that metabolize the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties. The therapeutic potential of nitrite and nitric oxide are widely recognized, although as yet, largely unrealized as delivery, let alone targeted delivery is extremely difficult. The company`s proprietary AOB offers the potential of a first-in-class natural delivery system for nitrite and nitric oxide.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.

Cortexyme

Cortexyme is developing therapeutics based on data supporting a new theory of the cause of Alzheimer`s and other neurodegenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currently testing several potential lead therapeutics in preclinical studies.

Bio Essence Corp

Bio Essence Corp is a Richmond, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accelerated Genetics

Accelerated Genetics is a Baraboo, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.